BioVie (BIVI) vs CalciMedica (CALC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie (BIVI) has outperformed CalciMedica (CALC) over the past year, losing 38.2% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | CALC |
|---|---|---|
| Share price | $0.80 | $1.26 |
| Market cap | $8.58M | $8.69M |
| 1-day change | -12.07% | +7.69% |
| YTD return | -31.03% | -96.18% |
| 1-year return | -38.22% | -92.34% |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.85 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.07M | $-29.56M |
| 52-week high | $3.79 | $36.00 |
| 52-week low | $0.7515 | $1.00 |
| Distance from 52-week high | -78.89% | -96.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +557.50% | +3868.25% |
| Average volume | 568.61K | 80.15K |
| Shares outstanding | 10.72M | 6.90M |
| Employees | 13 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed CALC by 54.1 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
BIVI vs CALC FAQ
Which is bigger, BioVie or CalciMedica?
CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.58M for BioVie (BIVI).
Which stock has performed better over the past year, BIVI or CALC?
BIVI returned -38.22% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and CalciMedica in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.